Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele
- PMID: 21185234
- DOI: 10.1016/S1474-4422(10)70306-9
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele
Abstract
Some patients with early-onset Alzheimer's disease (AD) present with a distinct phenotype. Typically, the first and most salient characteristic of AD is episodic memory impairment. A few patients, however, present with focal cortical, non-memory symptoms, such as difficulties with language, visuospatial, or executive functions. These presentations are associated with specific patterns of atrophy and frequently with a young age at onset. Age is not, however, the only determinant of phenotype; underlying factors, especially genetic factors, seem also to affect phenotype and predispose patients to younger or older age at onset. Importantly, patients with atypical early-onset disease seldom carry the APOE ɛ4 allele, which is the most important risk factor for lowering the age of onset in patients with AD. Additionally, theAPOE ɛ4 genotype seems to predispose patients to vulnerability in the medial temporal areas, which leads to memory loss. Conversely, patients negative for the APOE ɛ4 allele and with early-onset AD are more likely to be predisposed to vulnerability of cerebral networks beyond the medial temporal lobes. Other factors are probably involved in determining the pattern of atrophy, but these are currently unknown.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Comment in
-
Philip Scheltens: friendly face of Alzheimer's disease research.Lancet Neurol. 2011 Mar;10(3):208. doi: 10.1016/S1474-4422(11)70032-1. Lancet Neurol. 2011. PMID: 21349437 No abstract available.
Similar articles
-
Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.J Alzheimers Dis. 2016 Oct 4;54(3):913-922. doi: 10.3233/JAD-160373. J Alzheimers Dis. 2016. PMID: 27567841 Clinical Trial.
-
Segmented Linear Mixed Model Analysis Reveals Association of the APOEɛ4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression.J Alzheimers Dis. 2021;82(3):921-937. doi: 10.3233/JAD-210434. J Alzheimers Dis. 2021. PMID: 34120907 Free PMC article.
-
APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.BMC Neurol. 2008 Apr 16;8:9. doi: 10.1186/1471-2377-8-9. BMC Neurol. 2008. PMID: 18416843 Free PMC article.
-
Putative Survival Advantages in Young Apolipoprotein ɛ4 Carriers are Associated with Increased Neural Stress.J Alzheimers Dis. 2019;68(3):885-923. doi: 10.3233/JAD-181089. J Alzheimers Dis. 2019. PMID: 30814349 Free PMC article. Review.
-
Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer's disease: A review.Ageing Res Rev. 2016 May;27:15-22. doi: 10.1016/j.arr.2016.02.002. Epub 2016 Feb 11. Ageing Res Rev. 2016. PMID: 26876367 Free PMC article. Review.
Cited by
-
Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset.Alzheimers Dement. 2015 Nov;11(11):1349-57. doi: 10.1016/j.jalz.2014.12.007. Epub 2015 Apr 24. Alzheimers Dement. 2015. PMID: 25916562 Free PMC article.
-
Biomarkers in the primary progressive aphasias.Aphasiology. 2014 Sep;28(8-9):922-940. doi: 10.1080/02687038.2014.929631. Aphasiology. 2014. PMID: 25580048 Free PMC article.
-
Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease.Acta Pharm Sin B. 2024 Jul;14(7):2795-2814. doi: 10.1016/j.apsb.2024.03.034. Epub 2024 Apr 17. Acta Pharm Sin B. 2024. PMID: 39027235 Free PMC article. Review.
-
Apolipoprotein E ε-4 as a genetic determinant of Alzheimer's disease heterogeneity.Degener Neurol Neuromuscul Dis. 2015 Jun 12;5:9-18. doi: 10.2147/DNND.S41721. eCollection 2015. Degener Neurol Neuromuscul Dis. 2015. PMID: 32669910 Free PMC article. Review.
-
Alzheimer's disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation.Acta Neuropathol. 2019 Oct;138(4):597-612. doi: 10.1007/s00401-019-02036-6. Epub 2019 Jun 27. Acta Neuropathol. 2019. PMID: 31250152 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
